1
Tarran Jones
Mary M Bendig, Olivier J Leger, Jose Saldanha, S Tarran Jones, Ted A Yednock: Humanized antibodies against leukocyte adhesion molecule VLA-4. Athena Neurosciences, Townsend & Townsend & Crew, November 24, 1998: US05840299 (82 worldwide citation)

The invention provides humanized immunoglobulins that specifically bind to the VLA-4 ligand, and methods of treatment using the same. The methods are particularly useful for treatment of multiple sclerosis.


2
Tarran Jones
Paul D Ponath, Douglas J Ringler, S Tarran Jones, Walter Newman, José Saldanha, Mary M Bendig: Humanized immunoglobulin reactive with α4β7 integrin. Millennium Pharmaceuticals, Hamilton Brook Smith & Reynolds P C, December 12, 2006: US07147851 (32 worldwide citation)

The present invention relates to humanized immunoglobulins having binding specificity for α4β7 integrin, comprising an antigen binding region of nonhuman origin (e.g., rodent) and at least a portion of an immunoglobulin of human origin (e.g., a human framework region, a human constant region). In on ...


3
Tarran Jones
Mary M Bendig, Olivier J Leger, Jose Saldanha, Tarran S Jones, Ted A Yednock: Methods of inhibiting alpha-4-dependent interactions with VCAM-1 with anti-VLA-4 antibodies. Elan Pharmaceuticals, Crowell & Moring, August 21, 2012: US08246958 (31 worldwide citation)

The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host ...


4
Tarran Jones
Robert W Chestnut, Margaret J Polley, James C Paulson, S Tarran Jones, Jose W Saldanha, Mary M Bendig, Michael Kriegler, Carl Perez, Robert Bayer, Michael Nunn: Antibodies to P-selectin and their uses. Cytel Corporation, Campbell & Flores, September 1, 1998: US05800815 (24 worldwide citation)

The present invention relates to compositions and methods for treating inflammation and other pathological conditions using novel blocking P-selectin antibodies that inhibit adhesion of leukocytes to activated platelets and/or to activated vascular endothelium in vivo. Both murine and humanized anti ...


5
Tarran Jones
Mary M Bendig, Olivier J Leger, Jose Saldanha, Tarran S Jones, Ted A Yednock: Humanized anti-VLA4 immunoglobulins. Elan Pharaceuticals, Crowell & Moring, October 14, 2008: US07435802 (6 worldwide citation)

The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host ...


6
Tarran Jones
Robert W Chesnut, Margaret J Polley, James C Paulson, S Tarran Jones, Jose W Saldanha, Mary M Bendig, Michael Kriegler, Carl Perez, Robert Bayer, Michael Nunn: Method for detecting the presence of P-selectin. Cytel Corporation, Campbell & Flores, March 7, 2000: US06033667 (4 worldwide citation)

The present invention relates to compositions and methods for treating inflammation and other pathological conditions using novel blocking P-selectin antibodies that inhibit adhesion of leukocytes to activated platelets and/or to activated vascular endothelium in vivo. Both murine and humanized anti ...


7
Tarran Jones
Paul D Ponath, Douglas J Ringler, S Tarran Jones, Walter Newman, José Saldanha, Mary M Bendig: Humanized immunoglobulin reactive with α4β7 integrin. Millennium Pharmaceuticals, Hamilton Brook Smith & Reynolds P C, July 22, 2008: US07402410

The present invention relates to isolated nucleic acids encoding humanized immunoglobulins having binding specificity for α4β7 integrin, isolated nucleic acids encoding a humanized immunoglobulin heavy chain and isolated nucleic acids encoding a humanized light chain having binding specificity for α ...


8

9
Mary M Bendig, Catherine A Kettleborough, Jose Saldanha: Humanized and chimeric anti-epidermal growth factor receptor monoclonal antibodies. Merck Patent Gesellschaft Mit Beschrankter Haftung, Millen White Zelano & Branigan P C, September 24, 1996: US05558864 (156 worldwide citation)

Humanized and chimeric anti-epidermal growth factor receptor (anti-EGF-R) monoclonal antibodies are disclosed, comprising an artificial modified consensus sequence for the heavy chain of the framework region of the variable region of a human immunoglobulin. Corresponding humanized and chimeric monoc ...


10
A Cathrine Kettleborough, Mary M Bendig, Keith H Ansell, Detlef Gussow, Jaume Adan, Francesc Mitjans, Elisabet Rosell, Francesc Blasco, Jaume Piulats: Anti-EGFR single-chain Fvs and anti-EGFR antibodies. Merck Patent Gesellschaft mit Beschrankter Haftung, Millen White Zelano & Branigan P C, December 1, 1998: US05844093 (56 worldwide citation)

This invention relates to new anti-EGFR antibodies and single-chain Fvs (scFvs) thereof which can be obtained from phage-antibody libraries constructed from cells of an immunized mammalian, preferably a mouse. Two of the single-chain Fvs isolated from the phage-antibody libraries were engineered to ...



Click the thumbnails below to visualize the patent trend.